Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Nasus Pharma reports progress in its intranasal drug development programs for anaphylaxis and nausea, highlighting promising Phase 2 results for NS002 and upcoming pivotal study starts. The company appointed Brendan O’Grady as CEO and strengthened its cash position through recent funding to support operations into 2027.